Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Alliance Grants

McGill University

$50,667.00

Exploring strategies for the design of selective kinase inhibitors

EF 2024-25

Résumé
Kinases are a large class of enzymes essential for the control of various cellular processes including cell signaling and cell division. As such these enzymes are vital to cell growth and survival. Unfortunately, dysregulation of these enzymes affect their role as regulators of cell survival and proliferation leading to various forms of cancer. Blocking or reducing their activity is therefore a promising strategy in the search for cancer therapeutics, but kinase inhibitor selectivity is a major challenge for the development of safe and specific drugs. In particular, the structural similarity between kinases allows several inhibitors to block more than one kinase. Over the years, strategies to design selective kinase inhibitors have been sought after including computational and experimental strategies, although focusing primarily on one specific kinase. We propose to evaluate two distinct, more general approaches to develop selective kinase inhibitors. The first one is based on the introduction of macrocycles into known inhibitors, restricting their inherent flexibility to the bioactive form for a given kinase. The second one is based on the introduction of reactive groups specifically designed to react with binding site lysine residues.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
593436-2024
Name nom
Moitessier, Nicolas NRF
Department département
Chemistry
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
50667
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3705
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Bio-organic chemistry
Research subject fr
Chimie bio-organique
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Exploring strategies for the design of selective kinase inhibitors
Keywords
covalent inhibitors; kinase inhibitors; macrocycles; medicinal chemistry; selectivity
Application summary
Kinases are a large class of enzymes essential for the control of various cellular processes including cell signaling and cell division. As such these enzymes are vital to cell growth and survival. Unfortunately, dysregulation of these enzymes affect their role as regulators of cell survival and proliferation leading to various forms of cancer. Blocking or reducing their activity is therefore a promising strategy in the search for cancer therapeutics, but kinase inhibitor selectivity is a major challenge for the development of safe and specific drugs. In particular, the structural similarity between kinases allows several inhibitors to block more than one kinase. Over the years, strategies to design selective kinase inhibitors have been sought after including computational and experimental strategies, although focusing primarily on one specific kinase. We propose to evaluate two distinct, more general approaches to develop selective kinase inhibitors. The first one is based on the introduction of macrocycles into known inhibitors, restricting their inherent flexibility to the bioactive form for a given kinase. The second one is based on the introduction of reactive groups specifically designed to react with binding site lysine residues.